| 1.82 -0.04 (-2.15%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.23 | 1-year : | 2.32 |
| Resists | First : | 1.91 | Second : | 1.99 |
| Pivot price | 1.9 |
|||
| Supports | First : | 1.79 | Second : | 1.49 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 1.88 |
| MA(100) : | 2.02 |
MA(250) : | 2.04 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 14.2 |
D(3) : | 32.4 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 2.41 | Low : | 1.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SEER ] has closed below the lower bollinger band by 5.0%. Bollinger Bands are 27.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.86 - 1.88 | 1.88 - 1.89 |
| Low: | 1.79 - 1.8 | 1.8 - 1.82 |
| Close: | 1.8 - 1.82 | 1.82 - 1.84 |
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Wed, 07 Jan 2026
The Truth About Seer Inc: Is This ‘Future of Biotech’ Stock Secretly on Clearance? - AD HOC NEWS
Tue, 06 Jan 2026
Seer (NASDAQ:SEER) Trading 1.1% Higher - Here's Why - MarketBeat
Thu, 06 Nov 2025
Seer, Inc. Reports Third Quarter 2025 Financial Results Highlighting Revenue Growth and Increased Instrument Shipments - Quiver Quantitative
Thu, 06 Nov 2025
Earnings call transcript: Seer Q3 2025 reveals stable revenue, slight stock dip - Investing.com
Thu, 16 Oct 2025
Seer, Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 57.7 (%) |
| Shares Short | 256 (K) |
| Shares Short P.Month | 1,560 (K) |
| EPS | -1.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.86 |
| Profit Margin | 0 % |
| Operating Margin | -469.5 % |
| Return on Assets (ttm) | -15.2 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 0.29 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -1.37 |
| PEG Ratio | 0 |
| Price to Book value | 0.37 |
| Price to Sales | 6.25 |
| Price to Cash Flow | -2.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|